About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Maternal and Fetal Medicine Research Group has been recognized by AGAUR as a consolidated research group. It is a multidisciplinary team which integrates different knowledge areas in basic and clinical research. Basic research aims to identify new diagnostic and therapeutic tools in maternal and fetal pathologies, while clinical research intends to apply these tools in clinical practice.
The group has different investigation areas:
IP: Silvia Arévalo Martínez, Nerea Maiz Elizaran, Elena Carreras Moratonas, Carlota Rodó Rodríguez
IP: Preterm birth: Prediction and Prevention
IP: Miriam de Nadal Clanchet Collaborators: Anna González Tallada, Alberto Jauregui Abularach, Maria Alonso Alonso Funding agency: Instituto de Salud Carlos III Funding: 119185 Reference: PI20/00154 Duration: 01/01/2021 - 30/06/2025
IP: Melchor Carbonell Socias Collaborators: Julio Herrero García, Nerea Maiz Elizaran, Anna Suy Franch, Maria del Pilar Reimundo Diaz-Fierros Funding agency: Fundació La Marató de TV3 Funding: 49988.75 Reference: 202128-32 Duration: 20/10/2021 - 19/10/2024
IP: Carlota Rodó Rodríguez Collaborators: Pablo García Manau, Berta Serrano Sanchez, Francisco Barranco Martinez, Ester Del Barco Martínez Funding agency: Instituto de Salud Carlos III Funding: 162140 Reference: PI21/00601 Duration: 01/01/2022 - 30/06/2026
IP: Constanza Daigre Blanco Collaborators: Maia Brik Spinelli Funding agency: Ministerio Sanidad Funding: 35519 Reference: 2021I047 Duration: 22/12/2021 - 21/12/2024
Vall d’Hebron is part of the Consorcio INTERCOVID, which has analyzed over 6,500 pregnancies in 18 countries and observed a significant reduction in the risk of preeclampsia associated with vaccination.
Vall d’Hebron has taken part in a clinical trial whose results show improvements in endometrial regeneration and reproductive outcomes in patients with Asherman syndrome who had not responded to previous surgery.
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
